Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Paclitaxel→

Paclitaxel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
33069-62-4
Molecular formula
C47H51NO14
Molecular weight
853.9 g/mol
Drug class
Microtubule Inhibitor
Mechanism of action
Immunologic Adjuvants
Indications / reported uses
  • Breast Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Ovarian Neoplasms
  • Sarcoma, Kaposi
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Paclitaxel Environmental Risk Assessment (ERA) (the Paclitaxel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.